Visit Flagship at SITC | Booth #818.November 8-12, 2022.Stop by our booth to meet our new CSO Tom Turi, Ph.D., and talk with us about how we can partner with you for end-to-end biomarker support. Come learn about our new services, and pick up a map of our favorite...
Visit Flagship at World CB & CDx | Booth #4. Boston, MA | September 26-29, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support and see our latest data. Assay development and validation Clinical trial support...
Visit Flagship at AACR | Booth #1554. April 8-13, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries. Assay...
Utilizing RNAscope in the clinic to handle complex analysis. RNAscope is rapidly becoming a solution for understanding complex biomarker challenges. The benefits and awareness of image analysis in the space of pathology have been widely discussed and rapidly growing....
Technology Leads the Way to Precision Patient Care Digital transformation comes in many flavors. In pathology, it can be as simple as merely scanning pathology slides into whole slide images. However, it can also represent end-to-end digital pathology workflow...
Pathology Visions 2021October 17-19, 2021Digital Pathology: The Future is Here is the theme of this year’s Digital Pathology Association annual conference, Pathology Visions 2021. #PathVisions21 featured a poster from Flagship’s CCO Meredith James on a novel approach...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
Partnership to provide access to Flagship’s AI-aided software for quantifying PD-L1 IHC stains across various tissue typesNEW YORK, NY and BROOMFIELD, CO — February 17, 2022 — Paige, the global leader in AI-based diagnostic software in pathology, and Flagship...
Flagship Biosciences Earns Recognition as One of the Best Small Companies to Work For in ColoradoBroomfield, CO — January 5, 2022 — Today, Built In announced that Flagship Biosciences was honored in its 2022 Best Places To Work Awards. Specifically, Flagship...
PUBLICATIONS/POSTERS
Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor samples Measuring CD8 expression within tumor nests rather than averaging across a whole tissue section...
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology conference. We cover image analysis of tumor infiltrating lymphocytes (TIL) and more.
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in specifically identifying macrophages in PD-L1 stained tissues, but pathologists often have...